← back to search

Jonathan D. Licht

Van Andel Institute ·
Area of research
Molecular Biology · Hematology
Research interest
Research interests include Acute Myeloid Leukemia Research, Epigenetics and DNA Methylation, Protein Degradation and Inhibitors, and Histone Deacetylase Inhibitors Research.
h-index
88
citations
31,372
works
586
NIH funding
primary concept
email

Recent publications

Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR T cells
Blood 2025cited by 12position: middledoi
Recruitment of FBXO22 for targeted degradation of NSD2
Nature Chemical Biology 2024cited by 55position: middledoi
Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias
Nature Cancer 2023cited by 36position: middledoi
SMYD3 represses tumor-intrinsic interferon response in HPV-negative squamous cell carcinoma of the head and neck
Cell Reports 2023cited by 26position: middledoi
Recruitment of FBXO22 for Targeted Degradation of NSD2
bioRxiv (Cold Spring Harbor Laboratory) 2023cited by 4position: middledoi
BAP1 Loss Promotes Suppressive Tumor Immune Microenvironment via Upregulation of PROS1 in Class 2 Uveal Melanomas
Cancers 2022cited by 37position: middledoi
Low muscle mass is associated with a higher risk of all–cause and cardiovascular disease–specific mortality in cancer survivors
Nutrition 2022cited by 14position: middledoi
HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma
Cancer Gene Therapy 2022cited by 10position: middledoi
Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition
Molecular Cell 2021cited by 163position: middledoi
Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins
Cell Reports 2021cited by 112position: middledoi
Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture
Nature 2020cited by 263position: middledoi
FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML
Nature Communications 2020cited by 87position: middledoi
A Mutation in Histone H2B Represents a New Class of Oncogenic Driver
Cancer Discovery 2019cited by 104position: lastdoi
Decitabine limits escape from MEK inhibition in uveal melanoma
Pigment Cell & Melanoma Research 2019cited by 27position: middledoi
CTCF boundary remodels chromatin domain and drives aberrant HOX gene transcription in acute myeloid leukemia
Blood 2018cited by 90position: middledoi
EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis
Cancer Cell 2016cited by 249position: middledoi
DNA Hydroxymethylation Profiling Reveals that WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia
Cell Reports 2014cited by 261position: middledoi
Histone Methyltransferase MMSET/NSD2 Alters EZH2 Binding and Reprograms the Myeloma Epigenome through Global and Focal Changes in H3K36 and H3K27 Methylation
PLoS Genetics 2014cited by 238position: lastdoi
Single-cell nucleosome mapping reveals the molecular basis of gene expression heterogeneity
Proceedings of the National Academy of Sciences 2014cited by 112position: lastdoi
WHSC1 Promotes Oncogenesis through Regulation of NIMA-Related Kinase-7 in Squamous Cell Carcinoma of the Head and Neck
Molecular Cancer Research 2014cited by 101position: middledoi
Abstract 2344: 3D extracellular stiffness cues drive localized changes in gene expression
Cancer Research 2014cited by 0position: middledoi
Mitochondria Are Required for Antigen-Specific T Cell Activation through Reactive Oxygen Species Signaling
Immunity 2013cited by 1,281position: middledoi
EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
Cancer Cell 2013cited by 838position: middledoi
The Proto-oncometabolite Fumarate Binds Glutathione to Amplify ROS-Dependent Signaling
Molecular Cell 2013cited by 303position: middledoi
A physical sciences network characterization of non-tumorigenic and metastatic cells
Scientific Reports 2013cited by 181position: middledoi
Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies
Leukemia 2013cited by 146position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Teresa Ezponda · Navarre Institute of Health Research3 papers (2013–2014)Keiran S.M. Smalley · Moffitt Cancer Center3 papers (2019–2022) · 3 papers (2014–2019)Neil L. Kelleher · Northwestern University3 papers (2013–2019)J. William Harbour · The University of Texas Southwestern Medical Center3 papers (2019–2022)Navdeep S. Chandel · Northwestern University2 papers (2013–2013)Relja Popovic · AbbVie (United States)2 papers (2013–2014)Olivier Elemento · Cornell University2 papers (2014–2016)Christine Will · Friedrich-Alexander-Universität Erlangen-Nürnberg2 papers (2014–2019)Xiaoxiao Huang · Nantong University2 papers (2013–2019) · 2 papers (2019–2022)Yupeng Zheng · Beijing Tongren Hospital2 papers (2013–2014)Jan Liphardt · Stanford University2 papers (2014–2019)Michael F. Emmons · University of South Florida2 papers (2019–2022)Eva Martínez-García · Northwestern University2 papers (2013–2014)Ross L. Levine · Leukemia and Lymphoma Society2 papers (2013–2016)Jon A. Oyer · Pfizer (United States)2 papers (2013–2019)Chunjie Yu · University of Florida Health1 papers (2020–2020) · 1 papers (2020–2020)Katerina Hatzi · Cornell University1 papers (2016–2016)